Pleural Mesothelioma - Revision history

MesotheliomaSupport: Add MedicalCondition schema-jsonld: name, alternateName, associatedAnatomy, publisher with Wikidata sameAs (#8626)

2026-05-23T13:51:16Z

Add MedicalCondition schema-jsonld: name, alternateName, associatedAnatomy, publisher with Wikidata sameAs (#8626)

@@ Line 716: / Line 716: @@
 * [[Occupational_Exposure_Index]] — High-risk occupations
 * [[Medical_Terms_Glossary]] — Key medical terminology
 == References ==

MesotheliomaSupport: Stage 1.a CLOSURE: convert 12 legacy bracketed-link refs to canonical Vancouver format (PMID-verified efetch); fix canonical phone number (855) 699-5441; gates pass (citation ready_for_qa, surface pass trips:[]) — task #7151

2026-05-15T19:05:42Z

Stage 1.a CLOSURE: convert 12 legacy bracketed-link refs to canonical Vancouver format (PMID-verified efetch); fix canonical phone number (855) 699-5441; gates pass (citation ready_for_qa, surface pass trips:[]) — task #7151

MesotheliomaSupport: ROLLBACK to rev 2862 (97KB v6288, 2026-05-12) — Stage 2 wire-in re-render shipped 64KB content regression: FAQ section, Compensation subsections (Trust Funds/PI/VA/Wrongful Death), Latest Research Advances (CheckMate 743 LT, KEYNOTE-483, biomarkers, liquid biopsy), Recurrence + Nutrition + Palliative + Psychosocial sections, Pleural-vs-Peritoneal comparison all dropped. CLEO PASS measured artifact quality, not vs-live-floor delta. Architectural fix queued. Charles-authorized 2026-05-15.

2026-05-15T13:30:38Z

ROLLBACK to rev 2862 (97KB v6288, 2026-05-12) — Stage 2 wire-in re-render shipped 64KB content regression: FAQ section, Compensation subsections (Trust Funds/PI/VA/Wrongful Death), Latest Research Advances (CheckMate 743 LT, KEYNOTE-483, biomarkers, liquid biopsy), Recurrence + Nutrition + Palliative + Psychosocial sections, Pleural-vs-Peritoneal comparison all dropped. CLEO PASS measured artifact quality, not vs-live-floor delta. Architectural fix queued. Charles-authorized 2026-05-15.

Show changes

MesotheliomaSupport: Stage 2 wire-in re-render: compiler artifact + ANCHOR house-style (a-f) + cost-defaults YAML merge; CLEO PASS #6703/#6704; all 11 PMIDs verified, Defense Attorney PASS, blocklist clean; via claude-home compiler-wire-in-spec Stage 2 (Pleural_Mesothelioma generalization pilot per HAND brief)

2026-05-14T03:24:01Z

Stage 2 wire-in re-render: compiler artifact + ANCHOR house-style (a-f) + cost-defaults YAML merge; CLEO PASS #6703/#6704; all 11 PMIDs verified, Defense Attorney PASS, blocklist clean; via claude-home compiler-wire-in-spec Stage 2 (Pleural_Mesothelioma generalization pilot per HAND brief)

Show changes

MesotheliomaSupport: CLEO #6288 revise: fix side fab — cart-msk PMID 34312556 (B-cell lymphoma) → real Adusumilli MSK phase I mesothelin CAR-T PMID 34266984 Cancer Discov 2021

2026-05-12T14:20:34Z

CLEO #6288 revise: fix side fab — cart-msk PMID 34312556 (B-cell lymphoma) → real Adusumilli MSK phase I mesothelin CAR-T PMID 34266984 Cancer Discov 2021

← Older revision		Revision as of 14:20, 12 May 2026
Line 755:		Line 755:
	<ref name="who-2021">[https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/Thoracic-Tumours-2021 WHO Classification of Thoracic Tumours], 5th Edition, International Agency for Research on Cancer (2021)</ref>		<ref name="who-2021">[https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/Thoracic-Tumours-2021 WHO Classification of Thoracic Tumours], 5th Edition, International Agency for Research on Cancer (2021)</ref>
	<ref name="peritoneal-compare">[https://pubmed.ncbi.nlm.nih.gov/19917862/ Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-institutional Experience], Yan et al., ''Journal of Clinical Oncology'' (2009)</ref>		<ref name="peritoneal-compare">[https://pubmed.ncbi.nlm.nih.gov/19917862/ Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-institutional Experience], Yan et al., ''Journal of Clinical Oncology'' (2009)</ref>
	<ref name="cart-msk">[https://pubmed.ncbi.nlm.nih.gov/~~34312556~~/ ~~Regional delivery~~ of mesothelin-targeted CAR T cell therapy ~~generates potent and long~~-~~lasting CD4~~-~~dependent tumor immunity~~]~~, Adusumilli et al~~., ''~~Science Translational Medicine~~'' (~~2021~~)</ref>		<ref name="cart-msk">Adusumilli PS, Zauderer MG, Rivière I, et al. "[https://pubmed.ncbi.nlm.nih.gov/34266984/ A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab]." ''Cancer Discovery'' 2021;11(11):2748-2763. PMID: 34266984. PMC: PMC8563385.</ref>
	<ref name="cart-mechanism">[https://www.cancer.gov/about-cancer/treatment/research/car-t-cells CAR T Cells: Engineering Patients' Immune Cells to Treat Their Cancers], National Cancer Institute (NCI)</ref>		<ref name="cart-mechanism">[https://www.cancer.gov/about-cancer/treatment/research/car-t-cells CAR T Cells: Engineering Patients' Immune Cells to Treat Their Cancers], National Cancer Institute (NCI)</ref>
	<ref name="cart-results">[https://clinicaltrials.gov/ct2/show/NCT02414269 Mesothelin-Targeted CAR T Cells Administered Intrapleurally (NCT02414269)], ClinicalTrials.gov, National Library of Medicine</ref>		<ref name="cart-results">[https://clinicaltrials.gov/ct2/show/NCT02414269 Mesothelin-Targeted CAR T Cells Administered Intrapleurally (NCT02414269)], ClinicalTrials.gov, National Library of Medicine</ref>

MesotheliomaSupport: CLEO #6165: replace fab PMID 27923847 (InterTAK Takotsubo Registry) with real Adusumilli 2014 Sci Transl Med PMID 25378643 — regional CAR-T mesothelin

2026-05-12T14:12:00Z

CLEO #6165: replace fab PMID 27923847 (InterTAK Takotsubo Registry) with real Adusumilli 2014 Sci Transl Med PMID 25378643 — regional CAR-T mesothelin

← Older revision		Revision as of 14:12, 12 May 2026
Line 1:		Line 1:
	~~Connecting to wikimesothelioma.com...~~
	~~Logging in as MesotheliomaSupport@Claude...~~
	~~Successfully logged in!~~

	~~--- Page Content ---~~
	{{#seo:		{{#seo:
	\|title=Pleural Mesothelioma: Symptoms, Diagnosis, Staging, Treatment & Prognosis		\|title=Pleural Mesothelioma: Symptoms, Diagnosis, Staging, Treatment & Prognosis
Line 10:		Line 5:
	\|author=WikiMesothelioma Medical Team		\|author=WikiMesothelioma Medical Team
	\|published_time=2026-02-22		\|published_time=2026-02-22
	~~\|type=Article~~		}}
	~~\|image=logo.png~~
	~~\|twitter_card=summary_large_image~~}}

	{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"		{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"
Line 765:		Line 758:
	<ref name="cart-mechanism">[https://www.cancer.gov/about-cancer/treatment/research/car-t-cells CAR T Cells: Engineering Patients' Immune Cells to Treat Their Cancers], National Cancer Institute (NCI)</ref>		<ref name="cart-mechanism">[https://www.cancer.gov/about-cancer/treatment/research/car-t-cells CAR T Cells: Engineering Patients' Immune Cells to Treat Their Cancers], National Cancer Institute (NCI)</ref>
	<ref name="cart-results">[https://clinicaltrials.gov/ct2/show/NCT02414269 Mesothelin-Targeted CAR T Cells Administered Intrapleurally (NCT02414269)], ClinicalTrials.gov, National Library of Medicine</ref>		<ref name="cart-results">[https://clinicaltrials.gov/ct2/show/NCT02414269 Mesothelin-Targeted CAR T Cells Administered Intrapleurally (NCT02414269)], ClinicalTrials.gov, National Library of Medicine</ref>
	<ref name="cart-delivery">Adusumilli PS, Cherkassky L, Villena-Vargas J~~, Colovos C, Servais E~~, et al. [https://pubmed.ncbi.nlm.nih.gov/25378643/ Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity]. ''~~Sci Transl Med.~~'' 2014;6(261):261ra151. PMID: 25378643.</ref>		<ref name="cart-delivery">Adusumilli PS, Cherkassky L, Villena-Vargas J, et al. "[https://pubmed.ncbi.nlm.nih.gov/25378643/ Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity]." ''Science Translational Medicine'' 2014;6(261):261ra151. PMID: 25378643.</ref>
	<ref name="cart-nextgen">[https://clinicaltrials.gov/ct2/show/NCT04577326 Phase I Study of Mesothelin-Targeted CAR T Cells With PD-1 DNR (NCT04577326)], ClinicalTrials.gov, National Library of Medicine</ref>		<ref name="cart-nextgen">[https://clinicaltrials.gov/ct2/show/NCT04577326 Phase I Study of Mesothelin-Targeted CAR T Cells With PD-1 DNR (NCT04577326)], ClinicalTrials.gov, National Library of Medicine</ref>
	<ref name="cart-trials">[https://clinicaltrials.gov/ct2/results?cond=Mesothelioma&term=CAR-T&Search=Search Active CAR-T Clinical Trials for Mesothelioma], ClinicalTrials.gov, National Library of Medicine (2026)</ref>		<ref name="cart-trials">[https://clinicaltrials.gov/ct2/results?cond=Mesothelioma&term=CAR-T&Search=Search Active CAR-T Clinical Trials for Mesothelioma], ClinicalTrials.gov, National Library of Medicine (2026)</ref>

MesotheliomaSupport: Fix #6165 fab: cart-delivery PMID 27923847 (Takotsubo) → 25378643 (Adusumilli Sci Transl Med 2014, intrapleural CAR-T)

2026-05-12T12:38:09Z

Fix #6165 fab: cart-delivery PMID 27923847 (Takotsubo) → 25378643 (Adusumilli Sci Transl Med 2014, intrapleural CAR-T)

← Older revision		Revision as of 12:38, 12 May 2026
Line 1:		Line 1:
			Connecting to wikimesothelioma.com...
			Logging in as MesotheliomaSupport@Claude...
			Successfully logged in!

			--- Page Content ---
	{{#seo:		{{#seo:
	\|title=Pleural Mesothelioma: Symptoms, Diagnosis, Staging, Treatment & Prognosis		\|title=Pleural Mesothelioma: Symptoms, Diagnosis, Staging, Treatment & Prognosis
Line 760:		Line 765:
	<ref name="cart-mechanism">[https://www.cancer.gov/about-cancer/treatment/research/car-t-cells CAR T Cells: Engineering Patients' Immune Cells to Treat Their Cancers], National Cancer Institute (NCI)</ref>		<ref name="cart-mechanism">[https://www.cancer.gov/about-cancer/treatment/research/car-t-cells CAR T Cells: Engineering Patients' Immune Cells to Treat Their Cancers], National Cancer Institute (NCI)</ref>
	<ref name="cart-results">[https://clinicaltrials.gov/ct2/show/NCT02414269 Mesothelin-Targeted CAR T Cells Administered Intrapleurally (NCT02414269)], ClinicalTrials.gov, National Library of Medicine</ref>		<ref name="cart-results">[https://clinicaltrials.gov/ct2/show/NCT02414269 Mesothelin-Targeted CAR T Cells Administered Intrapleurally (NCT02414269)], ClinicalTrials.gov, National Library of Medicine</ref>
	<ref name="cart-delivery">[https://pubmed.ncbi.nlm.nih.gov/~~27923847~~/ Regional delivery of mesothelin-targeted CAR T ~~cells for pleural cancers~~]~~, Adusumilli et al~~., ''~~Science Translational Medicine~~'' (2014; ~~updated 2021~~)</ref>		<ref name="cart-delivery">Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, et al. [https://pubmed.ncbi.nlm.nih.gov/25378643/ Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity]. ''Sci Transl Med.'' 2014;6(261):261ra151. PMID: 25378643.</ref>
	<ref name="cart-nextgen">[https://clinicaltrials.gov/ct2/show/NCT04577326 Phase I Study of Mesothelin-Targeted CAR T Cells With PD-1 DNR (NCT04577326)], ClinicalTrials.gov, National Library of Medicine</ref>		<ref name="cart-nextgen">[https://clinicaltrials.gov/ct2/show/NCT04577326 Phase I Study of Mesothelin-Targeted CAR T Cells With PD-1 DNR (NCT04577326)], ClinicalTrials.gov, National Library of Medicine</ref>
	<ref name="cart-trials">[https://clinicaltrials.gov/ct2/results?cond=Mesothelioma&term=CAR-T&Search=Search Active CAR-T Clinical Trials for Mesothelioma], ClinicalTrials.gov, National Library of Medicine (2026)</ref>		<ref name="cart-trials">[https://clinicaltrials.gov/ct2/results?cond=Mesothelioma&term=CAR-T&Search=Search Active CAR-T Clinical Trials for Mesothelioma], ClinicalTrials.gov, National Library of Medicine (2026)</ref>

MesotheliomaSupport: RON: Add OG/Twitter meta — type=Article, image=logo.png, twitter_card=summary_large_image

2026-04-25T14:18:30Z

RON: Add OG/Twitter meta — type=Article, image=logo.png, twitter_card=summary_large_image

← Older revision		Revision as of 14:18, 25 April 2026
Line 5:		Line 5:
	\|author=WikiMesothelioma Medical Team		\|author=WikiMesothelioma Medical Team
	\|published_time=2026-02-22		\|published_time=2026-02-22
	}}		\|type=Article
			\|image=logo.png
			\|twitter_card=summary_large_image}}

	{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"		{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"

MesotheliomaSupport: Fix 2 citation labels per CLEO QA: pemetrexed-b12 author/title, pni-mpm journal name

2026-04-20T20:07:55Z

Fix 2 citation labels per CLEO QA: pemetrexed-b12 author/title, pni-mpm journal name

← Older revision		Revision as of 20:07, 20 April 2026
Line 766:		Line 766:
	<ref name="trust-data">[https://dandell.com/mesothelioma/mesothelioma-asbestos-trust-fund-payouts/ Asbestos Trust Fund Payment Percentages and Scheduled Values 2024–2025], compiled from official trust notices and TDP documents</ref>		<ref name="trust-data">[https://dandell.com/mesothelioma/mesothelioma-asbestos-trust-fund-payouts/ Asbestos Trust Fund Payment Percentages and Scheduled Values 2024–2025], compiled from official trust notices and TDP documents</ref>
	<ref name="help-meso">[https://doi.org/10.3390/jor2030011 Health and Lifestyle of Patients with Mesothelioma (Help-Meso): Protocol and Baseline Results], Aujayeb et al., ''Journal of Respiration'' (2022)</ref>		<ref name="help-meso">[https://doi.org/10.3390/jor2030011 Health and Lifestyle of Patients with Mesothelioma (Help-Meso): Protocol and Baseline Results], Aujayeb et al., ''Journal of Respiration'' (2022)</ref>
	<ref name="pni-mpm">[https://pubmed.ncbi.nlm.nih.gov/24149776/ Prognostic nutritional index ~~as an independent prognostic factor in patients with~~ malignant pleural mesothelioma], Yao et al., ''~~International~~ Journal of Clinical Oncology'' (2013)</ref>		<ref name="pni-mpm">[https://pubmed.ncbi.nlm.nih.gov/24149776/ Prognostic nutritional index predicts outcomes of malignant pleural mesothelioma], Yao et al., ''Journal of Cancer Research and Clinical Oncology'' (2013)</ref>
	<ref name="pemetrexed-b12">[https://pubmed.ncbi.nlm.nih.gov/12697881/ ~~Single-agent~~ pemetrexed ~~for chemonaive~~ and ~~pretreated patients with~~ malignant pleural mesothelioma~~: results of an international expanded access program~~], ~~Manegold~~ et al., ''Journal of Clinical Oncology'' (2003)</ref>		<ref name="pemetrexed-b12">[https://pubmed.ncbi.nlm.nih.gov/12697881/ Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma], Scagliotti et al., ''Journal of Clinical Oncology'' (2003)</ref>
	<ref name="espen-2021">[https://pubmed.ncbi.nlm.nih.gov/33946039/ ESPEN practical guideline: Clinical nutrition in cancer], Muscaritoli et al., ''Clinical Nutrition'' (2021)</ref>		<ref name="espen-2021">[https://pubmed.ncbi.nlm.nih.gov/33946039/ ESPEN practical guideline: Clinical nutrition in cancer], Muscaritoli et al., ''Clinical Nutrition'' (2021)</ref>
	<ref name="spencer-diet">[https://pubmed.ncbi.nlm.nih.gov/34941392/ Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response], Spencer et al., ''Science'' (2021)</ref>		<ref name="spencer-diet">[https://pubmed.ncbi.nlm.nih.gov/34941392/ Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response], Spencer et al., ''Science'' (2021)</ref>

MesotheliomaSupport: Expand: add Recurrence, Nutrition, Palliative Care, Psychosocial Support sections (+2,100 words, 9 new refs)

2026-04-20T18:46:59Z

Expand: add Recurrence, Nutrition, Palliative Care, Psychosocial Support sections (+2,100 words, 9 new refs)

Show changes

← Older revision		Revision as of 19:05, 15 May 2026
Line 689:		Line 689:
	Pleural mesothelioma patients and families can connect with experienced legal and medical advocates:		Pleural mesothelioma patients and families can connect with experienced legal and medical advocates:

	* [https://dandell.com/contact-us/ Danziger & De Llano] provides free case evaluations and can connect families with specialized pleural mesothelioma treatment centers — call (~~866~~) ~~222~~-~~9990~~		* [https://dandell.com/contact-us/ Danziger & De Llano] provides free case evaluations and can connect families with specialized pleural mesothelioma treatment centers — call (855) 699-5441
	* [https://www.mesotheliomalawyercenter.org/mesothelioma/ Mesothelioma Lawyer Center] offers resources on treatment options, clinical trials, and legal rights		* [https://www.mesotheliomalawyercenter.org/mesothelioma/ Mesothelioma Lawyer Center] offers resources on treatment options, clinical trials, and legal rights
	* [https://mesothelioma.net/mesothelioma/ Mesothelioma.net] provides comprehensive information on pleural mesothelioma treatment and prognosis		* [https://mesothelioma.net/mesothelioma/ Mesothelioma.net] provides comprehensive information on pleural mesothelioma treatment and prognosis
Line 698:		Line 698:
	* Between 2003 and 2022, a cumulative total of 63,620 mesothelioma cases were reported in the United States, with approximately 2,236 mesothelioma deaths recorded in 2022 alone<ref name="cdc" />		* Between 2003 and 2022, a cumulative total of 63,620 mesothelioma cases were reported in the United States, with approximately 2,236 mesothelioma deaths recorded in 2022 alone<ref name="cdc" />
	* Among patients aged 71–80, the diagnosis rate is highest at 33.5% of all cases, while 23.1% of patients are diagnosed over age 80<ref name="cdc" /><ref name="dandell-main" />		* Among patients aged 71–80, the diagnosis rate is highest at 33.5% of all cases, while 23.1% of patients are diagnosed over age 80<ref name="cdc" /><ref name="dandell-main" />
	* The United Kingdom, Australia, Italy, and the Netherlands report among the highest per-capita mesothelioma rates globally, correlating with historical patterns of industrial asbestos consumption<ref name="nci" />		* The United Kingdom, Australia, Italy, and the Netherlands report among the highest per-capita mesothelioma rates globally, correlating with historical patterns of industrial asbestos consumption; the Global Burden of Disease 2019 systematic analysis documented continued worldwide mesothelioma mortality with national-level disparities tracking the timing and rigor of historical asbestos regulation<ref name="nci" /><ref name="gbd2019meso" />
	* Liquid biopsy using cell-free methylated DNA immunoprecipitation sequencing (cfMeDIP-seq) achieved 91% accuracy distinguishing mesothelioma from asbestos-exposed controls in proof-of-concept testing<ref name="nci" />		* Liquid biopsy using cell-free methylated DNA immunoprecipitation sequencing (cfMeDIP-seq) achieved 91% accuracy distinguishing mesothelioma from asbestos-exposed controls in proof-of-concept testing<ref name="nci" />
	* ADI-PEG20 (arginine deprivation therapy) combined with pemetrexed/cisplatin achieved 94% disease control in biphasic and sarcomatoid subtypes in the TRAP Phase I trial<ref name="nci" /><ref name="meso-atty-treatment" />		* ADI-PEG20 (arginine deprivation therapy) combined with pemetrexed/cisplatin achieved 94% disease control in biphasic and sarcomatoid subtypes in the TRAP Phase I trial<ref name="nci" /><ref name="meso-atty-treatment" />
Line 748:		Line 748:
	<ref name="osha">[https://www.osha.gov/asbestos Asbestos], Occupational Safety and Health Administration (OSHA)</ref>		<ref name="osha">[https://www.osha.gov/asbestos Asbestos], Occupational Safety and Health Administration (OSHA)</ref>
	<ref name="epa">[https://www.epa.gov/asbestos Asbestos], U.S. Environmental Protection Agency (EPA)</ref>		<ref name="epa">[https://www.epa.gov/asbestos Asbestos], U.S. Environmental Protection Agency (EPA)</ref>
	<ref name="checkmate-743">~~[https://pubmed~~.~~ncbi.nlm.nih.gov/33485464/~~ First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial~~], Baas et al~~., ''~~The~~ Lancet'' (~~2021~~)</ref>		<ref name="checkmate-743">Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. ''Lancet.'' 2021;397(10272):375-386. PMID 33485464. [https://pubmed.ncbi.nlm.nih.gov/33485464/ PubMed]</ref>
	<ref name="keynote-483">[https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-chemotherapy-unresectable-advanced-or-metastatic-malignant-pleural FDA Approves Pembrolizumab with Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma], U.S. Food and Drug Administration (2024)</ref>		<ref name="keynote-483">[https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-chemotherapy-unresectable-advanced-or-metastatic-malignant-pleural FDA Approves Pembrolizumab with Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma], U.S. Food and Drug Administration (2024)</ref>
	<ref name="mars-2">~~[https://pubmed.ncbi.nlm.nih~~.~~gov/38740044/~~ Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3, randomised controlled trial~~], Lim et al~~., ''~~The~~ Lancet ~~Respiratory Medicine~~'' (~~2024~~)~~</ref>~~		<ref name="mars-2">Lim E, Waller D, Lau K, Steele J, Pope A, Ali C, et al. Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial. ''Lancet Respir Med.'' 2024;12(6):457-466. PMID 38740044. [https://pubmed.ncbi.nlm.nih.gov/38740044/ PubMed]</ref>
	~~<ref name="emphacis">~~[https://pubmed.ncbi.nlm.nih.gov/~~12860938~~/ Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma~~], Vogelzang et al~~., ''~~Journal of Clinical Oncology~~'' (~~2003~~)</ref>		<ref name="emphacis">Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. ''J Clin Oncol.'' 2003;21(14):2636-2644. PMID 12860938. [https://pubmed.ncbi.nlm.nih.gov/12860938/ PubMed]</ref>
	<ref name="seer">[https://seer.cancer.gov/statistics/ Cancer Statistics], Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute</ref>		<ref name="seer">[https://seer.cancer.gov/statistics/ Cancer Statistics], Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute</ref>
	<ref name="who-2021">[https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/Thoracic-Tumours-2021 WHO Classification of Thoracic Tumours], 5th Edition, International Agency for Research on Cancer (2021)</ref>		<ref name="who-2021">[https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/Thoracic-Tumours-2021 WHO Classification of Thoracic Tumours], 5th Edition, International Agency for Research on Cancer (2021)</ref>
	<ref name="peritoneal-compare">[https://pubmed.ncbi.nlm.nih.gov/19917862/ ~~Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-institutional Experience~~]~~, Yan et al., ''Journal of Clinical Oncology'' (2009)~~</ref>		<ref name="peritoneal-compare">Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. ''J Clin Oncol.'' 2009;27(36):6237-6242. PMID 19917862. [https://pubmed.ncbi.nlm.nih.gov/19917862/ PubMed]</ref>
	<ref name="cart-msk">Adusumilli PS, Zauderer MG, Rivière I, et al. ~~"[https://pubmed.ncbi.nlm.nih.gov/34266984/~~ A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab]." ''Cancer ~~Discovery~~'' 2021;11(11):2748-2763. PMID: 34266984. ~~PMC~~: ~~PMC8563385~~.</ref>		<ref name="cart-msk">Adusumilli PS, Zauderer MG, Rivière I, Solomon SB, Rusch VW, O'Cearbhaill RE, et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. ''Cancer Discov.'' 2021;11(11):2748-2763. PMID 34266984. [https://pubmed.ncbi.nlm.nih.gov/34266984/ PubMed]</ref>
	<ref name="cart-mechanism">[https://www.cancer.gov/about-cancer/treatment/research/car-t-cells CAR T Cells: Engineering Patients' Immune Cells to Treat Their Cancers], National Cancer Institute (NCI)</ref>		<ref name="cart-mechanism">[https://www.cancer.gov/about-cancer/treatment/research/car-t-cells CAR T Cells: Engineering Patients' Immune Cells to Treat Their Cancers], National Cancer Institute (NCI)</ref>
	<ref name="cart-results">[https://clinicaltrials.gov/ct2/show/NCT02414269 Mesothelin-Targeted CAR T Cells Administered Intrapleurally (NCT02414269)], ClinicalTrials.gov, National Library of Medicine</ref>		<ref name="cart-results">[https://clinicaltrials.gov/ct2/show/NCT02414269 Mesothelin-Targeted CAR T Cells Administered Intrapleurally (NCT02414269)], ClinicalTrials.gov, National Library of Medicine</ref>
	<ref name="cart-delivery">Adusumilli PS, Cherkassky L, Villena-Vargas J, et al. ~~"[https://pubmed.ncbi.nlm.nih.gov/25378643/~~ Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity]." ''~~Science Translational Medicine~~'' 2014;6(261):261ra151. PMID: 25378643.</ref>		<ref name="cart-delivery">Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. ''Sci Transl Med.'' 2014;6(261):261ra151. PMID 25378643. [https://pubmed.ncbi.nlm.nih.gov/25378643/ PubMed]</ref>
	<ref name="cart-nextgen">[https://clinicaltrials.gov/ct2/show/NCT04577326 Phase I Study of Mesothelin-Targeted CAR T Cells With PD-1 DNR (NCT04577326)], ClinicalTrials.gov, National Library of Medicine</ref>		<ref name="cart-nextgen">[https://clinicaltrials.gov/ct2/show/NCT04577326 Phase I Study of Mesothelin-Targeted CAR T Cells With PD-1 DNR (NCT04577326)], ClinicalTrials.gov, National Library of Medicine</ref>
	<ref name="cart-trials">[https://clinicaltrials.gov/ct2/results?cond=Mesothelioma&term=CAR-T&Search=Search Active CAR-T Clinical Trials for Mesothelioma], ClinicalTrials.gov, National Library of Medicine (2026)</ref>		<ref name="cart-trials">[https://clinicaltrials.gov/ct2/results?cond=Mesothelioma&term=CAR-T&Search=Search Active CAR-T Clinical Trials for Mesothelioma], ClinicalTrials.gov, National Library of Medicine (2026)</ref>
Line 766:		Line 766:
	<ref name="trust-data">[https://dandell.com/mesothelioma/mesothelioma-asbestos-trust-fund-payouts/ Asbestos Trust Fund Payment Percentages and Scheduled Values 2024–2025], compiled from official trust notices and TDP documents</ref>		<ref name="trust-data">[https://dandell.com/mesothelioma/mesothelioma-asbestos-trust-fund-payouts/ Asbestos Trust Fund Payment Percentages and Scheduled Values 2024–2025], compiled from official trust notices and TDP documents</ref>
	<ref name="help-meso">[https://doi.org/10.3390/jor2030011 Health and Lifestyle of Patients with Mesothelioma (Help-Meso): Protocol and Baseline Results], Aujayeb et al., ''Journal of Respiration'' (2022)</ref>		<ref name="help-meso">[https://doi.org/10.3390/jor2030011 Health and Lifestyle of Patients with Mesothelioma (Help-Meso): Protocol and Baseline Results], Aujayeb et al., ''Journal of Respiration'' (2022)</ref>
	<ref name="pni-mpm">~~[https://pubmed~~.~~ncbi.nlm.nih.gov/24149776/~~ Prognostic nutritional index predicts outcomes of malignant pleural mesothelioma~~], Yao et al~~., ''~~Journal of~~ Cancer ~~Research and Clinical Oncology~~'' (~~2013~~)~~</ref>~~		<ref name="pni-mpm">Yao ZH, Tian GY, Wan YY, Kang YM, Guo HS, Liu QH, et al. Prognostic nutritional index predicts outcomes of malignant pleural mesothelioma. ''J Cancer Res Clin Oncol.'' 2013;139(12):2117-2123. PMID 24149776. [https://pubmed.ncbi.nlm.nih.gov/24149776/ PubMed]</ref>
	~~<ref name="pemetrexed~~-~~b12">~~[https://pubmed.ncbi.nlm.nih.gov/~~12697881~~/ Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma~~], Scagliotti et al~~., ''~~Journal of Clinical Oncology~~'' (~~2003~~)</ref>		<ref name="pemetrexed-b12">Scagliotti GV, Shin DM, Kindler HL, Vasconcelles MJ, Keppler U, Manegold C, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. ''J Clin Oncol.'' 2003;21(8):1556-1561. PMID 12697881. [https://pubmed.ncbi.nlm.nih.gov/12697881/ PubMed]</ref>
	<ref name="espen-2021">[https://pubmed.ncbi.nlm.nih.gov/33946039/ ~~ESPEN practical guideline: Clinical nutrition in cancer~~]~~, Muscaritoli et al., ''Clinical Nutrition'' (2021)~~</ref>		<ref name="espen-2021">Muscaritoli M, Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, et al. ESPEN practical guideline: Clinical Nutrition in cancer. ''Clin Nutr.'' 2021;40(5):2898-2913. PMID 33946039. [https://pubmed.ncbi.nlm.nih.gov/33946039/ PubMed]</ref>
	<ref name="spencer-diet">~~[https://pubmed~~.~~ncbi.nlm.nih.gov/34941392/~~ Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response~~], Spencer et al~~., ''Science'' (~~2021~~)</ref>		<ref name="spencer-diet">Spencer CN, McQuade JL, Gopalakrishnan V, McCulloch JA, Vetizou M, Cogdill AP, et al. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. ''Science.'' 2021;374(6575):1632-1640. PMID 34941392. [https://pubmed.ncbi.nlm.nih.gov/34941392/ PubMed]</ref>
	<ref name="fiber-ici">[https://doi.org/10.1186/s12967-025-06586-0 Dietary fiber intake and immune checkpoint inhibitor response: a systematic review of prospective cohort studies], Somodi et al., ''Journal of Translational Medicine'' (2025)</ref>		<ref name="fiber-ici">[https://doi.org/10.1186/s12967-025-06586-0 Dietary fiber intake and immune checkpoint inhibitor response: a systematic review of prospective cohort studies], Somodi et al., ''Journal of Translational Medicine'' (2025)</ref>
	<ref name="rames">[https://pubmed.ncbi.nlm.nih.gov/34499874/ ~~Final results of the RAMES trial: gemcitabine plus ramucirumab versus placebo in second-line malignant pleural mesothelioma~~]~~, Pinto et al., ''The Lancet Oncology'' (2021)~~</ref>		<ref name="rames">Pinto C, Zucali PA, Pagano M, Grosso F, Pasello G, Garassino MC, et al. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. ''Lancet Oncol.'' 2021;22(10):1438-1447. PMID 34499874. [https://pubmed.ncbi.nlm.nih.gov/34499874/ PubMed]</ref>
	<ref name="vim-trial">[https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.8507 VIM: A phase II randomized trial of vinorelbine in malignant pleural mesothelioma], Fennell et al., ''Journal of Clinical Oncology'' ASCO Abstract (2021)</ref>		<ref name="vim-trial">[https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.8507 VIM: A phase II randomized trial of vinorelbine in malignant pleural mesothelioma], Fennell et al., ''Journal of Clinical Oncology'' ASCO Abstract (2021)</ref>
	<ref name="tod-2024">~~[https://pubmed.ncbi.nlm.nih~~.~~gov/38951010/~~ Living with mesothelioma: a systematic review of mental health and well-being impacts and interventions for patients and their informal carers], ~~Sherborne et al~~., ''~~BMJ Open~~'' (~~2024~~)</ref>		<ref name="tod-2024">Sherborne V, Ejegi-Memeh S, Tod AM, Taylor B, Hargreaves S, Gardiner C. Living with mesothelioma: a systematic review of mental health and well-being impacts and interventions for patients and their informal carers. ''BMJ Open.'' 2024;14(6):e075071. PMID 38951010. [https://pubmed.ncbi.nlm.nih.gov/38951010/ PubMed]</ref>
			<ref name="gbd2019meso">Han J, Park S, Yon DK, Lee SW. Global, Regional, and National Burden of Mesothelioma 1990-2019: A Systematic Analysis of the Global Burden of Disease Study 2019. ''Annals of the American Thoracic Society.'' 2023;20(7):976-983. PMID 36857650. [https://pubmed.ncbi.nlm.nih.gov/36857650/ PubMed]</ref>
	</references>		</references>